Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis

Thrombosis and Haemostasis

Volumn 76, Issue 2, 1996, Pages 195-199

  Fiessinger, J N ^a   Lopez Fernandez, M ^b   Gatterer, E ^c   Granqvist, S ^d   Kher, A ^e   Olsson, C G ^f   Soderberg K ^g  

^a HÔPITAL BROUSSAIS   (France)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e Pharmacia Biosensor AB   (France)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHLEBOGRAPHY; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0029842386     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650553     Document Type: Article

References (15)

1. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Loerum F, Scheel B, Sortland O, Vinje B. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis; 16 (Suppl 2): 30-7.
2. Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, Toulemonde F, Bassand JP, Maurat JP. A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study. Presse Med 1988; 17 (5): 197-200.
3. Bratt G, Aberg W, Törnebohm E, Granqvist S, Lockner D. Subcutaneous Kabi 2165 in the treatment of deep venous thrombosis (DVT) of the leg. Thromb Res 1987; VII (Suppl): 24 (abstract).
4. Bratt G, Aberg W, Törnebohm E, Johansson M, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin® as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-10.
5. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601-7.
6. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-451.
7. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304.
8. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenblomm D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
9. Holmström M, Berglund MC, Granquist S, Bratt G, Törnebohm E, Lockner D. Fragmin® once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992; 67: 49-55.
10. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
11. Etude Multicentrique. Traitement des thromboses veineuses profondes constituées. Etude comparative d'un fragment d'héparine de bas poids moléculaire (Fragmine®) administré par voie sous-cutanée et de l'héparine standard administrée par voie intraveineuse continue. Rev Med Interne 1989; 10: 375-81.
12. A collaborative European multicenter study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251-6.
13. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sié P, Silsiguen M, Combe S. Subcutanous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153: 1541-6.
14. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-29.
15. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN for the Fragmin-Study group. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin® in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 698-702.